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Abstract
Background: In vitro hemolysis, the prevailing cause
of preanalytical error in routine laboratory diagnos-
tics, might influence the reliability of several tests,
affect the quality of the total testing process and
jeopardize patient safety. Although laboratory instru-
mentation is now routinely equipped with systems
capable of automatically testing and eventually cor-
recting for hemolysis interference, to our knowledge
there are no reports that have compared the efficiency
of different analytical platforms for identifying and
classifying specimens with hemolysis.
Methods: Serum from a healthy volunteer was spiked
with varying amounts of hemolyzed blood from the
same volunteer, providing a serum free hemoglobin
concentration ranging from 0.0 g/L to 2.0 g/L as meas-
ured by the reference cyanmethemoglobin assay. The
spiked serum samples were shipped to seven sepa-
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rate laboratories and the hemolysis index (HI) was
tested in triplicate on the following analytical plat-
forms: Roche Modular System P (ns4) and Integra
400 Plus (ns1), Siemens Dimension RxL (ns3),
ADVIA 2400 (ns1) and ADVIA 1800 (ns1), Olympus
AU 680 (ns1) and Coulter DXC 800 (ns1).
Results: Satisfactory agreement of HI results was
observed among the various analytical platforms,
despite a trend toward overestimation by the ADVIA
2400 and 1800. After normalizing results according
to the instrument-specific alert value, discrepancies
were considerably reduced. All instruments except for
the Dimension RxL gave values normalized to the
instrument-specific alert value, -1.0 for the sample
with 0.048 g/L free hemoglobin, and)1.0 for the sam-
ple with 0.075 g/L free hemoglobin. The results of the
four Modular System P tests were also highly repro-
ducible among the different facilities. When evaluat-
ing instruments that provided quantitative HI results,
the mean intra-assay coefficient of variation (CV) cal-
culated for the triplicate determinations was always
between 0.1% and 2.7%.
Conclusions: The results of this multicenter evalua-
tion confirm that efficiency of different analytical plat-
forms to correctly identify and classify unsuitable
samples is satisfactory. However, more effort should
be placed on the standardization of reporting HI. All
the instruments that we tested provide either quanti-
tative or qualitative results that are essentially com-
parable, but which should always be compared with
the instrument-specific alert values to harmonize their
efficiency.
Clin Chem Lab Med 2009;47:934–9.
Keywords: errors; hemolysis; hemolysis index (HI);
patient safety; preanalytical variability.
Introduction
Preanalytical variability is a major problem in labor-
atory diagnostics because several phases of this pro-
cess can affect specimen integrity and the reliability
of test results. Spurious test results obtained on
unsuitable specimens not only impact the quality of
the total testing process, but might produce adverse
clinical and economic outcomes. Several lines of
evidence show that in vitro hemolysis is the most
prevalent preanalytical error; its frequency reportedly
affecting as many as 3.3% of routine samples referred
to the clinical laboratory, and accounting for up to
70% of all the unsuitable specimens received (1–7).
Hemolysis is commonly defined as the release of
hemoglobin from erythrocytes into the surrounding
plasma as a result of damage or breakdown of the
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Table 1 Description of centers and instrumentation.
Laboratory Instrumentsa
University Hospital, Verona, Italy Roche Modular System P and Siemens Dimension RxL
University Hospital, Padova, Italy Roche Modular System P and Siemens Dimension RxL
San Bortolo Hospital, Vicenza, Italy Siemens ADVIA 2400 and 1800
Hoˆpital Saint Antoine, Paris, France Olympus AU 680 and Beckman Coulter DxC 800
University Hospital, Leuven, Belgium Roche Modular System P and Siemens Dimension RxL
University Hospital, Hradec Kralove, Czech Republic Roche Modular System P
BD PAS, European Clinical Laboratory, Plymouth, UK Roche Integra 400 Plus
aF. Hoffmann-La Roche Ltd., Basel, Switzerland; Siemens Healthcare Diagnostics Inc., Deerfield, IL, USA; Olympus Medical
System Corp., Tokyo, Japan; Beckman Coulter Inc., Fullerton, CA, USA.
cell membrane. Hemolysis confers a pink to red hue
coloration of the plasma or serum following centri-
fugation of specimens. Traditionally, the upper ref-
erence limit for free hemoglobin varies from 0.02
mg/L (plasma) to 0.05 mg/L (serum), and it becomes
visually detectable when such concentration exceeds
0.3–0.6 g/L (18.8–37.6 mmol/L), corresponding rough-
ly to 0.5%–1.0% of lysed erythrocytes (7).
The interference effect from hemolysis in laboratory
diagnostics is a consequence of several coexisting
biological and analytical causes, including (a) leakage
of hemoglobin and other intracellular components
into the surrounding fluid thereby producing false ele-
vations of intracellular analytes or dilutional effects,
(b) method- and analyte-dependent spectrophoto-
metric interferences and (c) chemical interference in
a variety of analytic reactions. At high concentrations
of serum hemoglobin, all these interference effects
might coexist, thereby producing spurious variations
that do not necessarily follow the same pattern result-
ing in overestimation or underestimation (1, 2, 7, 8).
The magnitude of this problem is further magnified
by the management of hemolytic specimens in the
laboratory, from their identification to the optimal
means of handling them. One of the more debated
issues is the identification of hemolysis by laboratory
personnel, because hemolysis in serum or plasma is
undetectable until the specimen has been centrifuged.
However, even following centrifugation there are no
definitive guidelines, other than recommendations or
suggestions, that define what means should be used
to assess the degree of hemolysis or what thresholds
should be used to guide the rejection of samples (7).
In vitro hemolysis has traditionally been assessed
on an arbitrary basis through visual inspection by lab-
oratory personnel. More recently, however, several
preanalytical modules and analytical platforms have
been equipped with systems capable of automatically
testing and eventually correcting for a broad series of
analytical interferences, including hemolysis. In most
cases, the instruments report a qualitative or quanti-
tative ‘‘hemolysis index’’ (HI), which should be
compared with manufacturer-, instrument- and ana-
lyte-specific alert values before deciding whether to
perform testing. This process is not intended for diag-
nostic purposes, but instead used to determine the
condition of a sample. The user often can adjust the
level at which the interference generates a flag, and
also can customize the operating mode to reflect their
own individual operating requirements for reporting
interference. The implementation of this technology
offers several advantages. It can overcome the inher-
ent limits of visual inspection and it helps to improve
the recognition of specimens with mild hemolysis
(;0.6 g/L of free hemoglobin) which are difficult to
detect by visual inspection but might still be unsuit-
able for the measurements of several analytes such
as aspartate aminotransferase, lactate dehydrogen-
ase and potassium (8). The index may also be useful
as a quality assurance indicator to evaluate and
improve the best preanalytical practices among dif-
ferent blood collection sites or hospital wards. Finally,
the automated HI allows standardization and harmo-
nization of behavior among operators in the same lab-
oratory or among different facilities. Although
widespread implementation of this technology is thus
advantageous, advisable and even recommended (7,
9), there are no reports, to the best of our knowledge,
that have compared the efficiency of different analyt-
ical platforms for the identification and correct clas-
sification of hemolyzed specimens.
Materials and methods
The preparation of the samples was performed at a central
location in the Clinical Chemistry Laboratory of the Verona
University Hospital. On the morning of day 1, 50 mL of blood
were collected from a healthy volunteer into 10 siliconized
vacuum tubes containing no additives (BD Vacutainer
Serum Glass Tubes, 5.0 mL; Cat 367614, Becton Dickinson
UK Ltd, Plymouth, UK), using a BD Vacutainer Multi-sample
21G needle (Becton Dickinson). One 5 mL specimen (hemo-
lyzed sample – 5 mL of whole blood) was immediately
stored at –708C, whereas the other nine samples were
centrifuged at 1500=g for 10 min at room temperature. The
serum was separated and pooled from the nine tubes, cre-
ating ;22 mL (pooled sample), and also stored at –708C. On
the morning of day 2, the hemolysed sample and the pooled
sample were thawed and re-centrifuged at 1500=g for
10 min. Free hemoglobin was quantitated in the supernatant
of the hemolyzed sample by the reference cyanmethemoglo-
bin method using a UV-1700 spectrophotometer (Shimadzu
Italia S.l.r., Milan, Italy) (10). Five serial dilutions of free
serum hemoglobin were further prepared by mixing serial
aliquots of hemolyzed sample and pooled sample to achieve
final free hemoglobin concentrations ranging from 0.09 g/L
to 2.0 g/L (labeled as Sample A, B, C, D and E). These con-
centrations approximately cover the degree of hemolysis
seen in most hemolyzed samples encountered by clinical
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Table 2 Description of the instrumentation used to test the hemolysis index (HI) and the instrument-specific alert values.
Manufacturer Instrument Alert value (free hemoglobin)
Beckman Coulter DxC 800 2 (arbitrary unit, corresponding to 0.50–1.0 g/L)
Olympus AU 680 ‘‘q’’ (arbitrary unit, corresponding to 0.50–1.0 g/L)
Roche Modular System P 0.60 g/L
Roche Integra 400 PLUS 0.60 g/L
Siemens RxL Dimension 2 (arbitrary unit, corresponding to 0.25–0.50 g/L)
Siemens ADVIA 2400 0.80 g/La
Siemens ADVIA 1800 0.80 g/La
aArbitrary cut-off established by the local operator.
laboratories (4). For each of these separate samples, seven
aliquots of 0.6 mL each were transferred into 1 mL plastic
cups and shipped to the laboratories participating
in this study (Table 1). Samples were kept stored until all
laboratories had received their samples. The tests were
performed simultaneously in the seven laboratories partici-
pating in the study. Before assessment, the samples were
mixed manually by 5–6 complete inversions. The HI was
tested on each sample (from A to E) in triplicate on the ana-
lytical platforms reported in Table 3, and quantitative results
were reported as mean"SD. Concomitantly, the hemoglobin
concentration of each sample was retested by the cyanme-
themoglobin method in the Clinical Chemistry Laboratory of
the Verona University Hospital. When quantitative results
were available, results were normalized to the instrument-
specific alert value (i.e., measured value/alert value) as pro-
vided by the manufacturers (Table 2). In addition, an
arbitrary threshold of free hemoglobin measured by the
cyanmethemoglobin method was established at 0.6 g/L. This
concentration of free hemoglobin is suggestive of a mildly
hemolyzed specimen and represents the threshold for decid-
ing whether some test results might already be significantly
affected by in vitro hemolysis (e.g., aspartate aminotransfe-
rase, lactate dehydrogenase and potassium) (8).
Results
The results of this multicenter evaluation of the HI are
shown in Tables 3 and 4. No variation in the free
hemoglobin concentration in the specimens was
observed prior to and following shipment, as verified
by the cyanmethemoglobin measurement (Passing
and Bablok regression analysis and Pearson correla-
tion coefficient: wbefore shipmentxs1.02=wafter
shipmentxq0.01; rs1.00; p-0.001). Satisfactory
agreement was observed among the various analyti-
cal platforms, despite the presence of a trend toward
overestimation by both the ADVIA 2400 and 1800
Dimension (Table 3). However, after normalizing
results according to the instrument-specific alert
value (i.e., wmeasured valuex/w0.6 g/Lx for the cyan-
methemoglobin method, and wmeasured valuex/
whighest alert valuex for the instruments), such dis-
crepancies were considerably reduced (Table 4). In
particular, all instruments except for the RxL Dimen-
sion gave ‘‘normalized’’ values -1.0 for sample B
(free hemoglobin value of 0.048 g/L by the cyanme-
themoglobin method) and )1.0 for sample C (free
hemoglobin value of 0.075 g/L by the cyanmethemo-
globin method). The quantitative HI results obtained
on the Modular System P were also highly reproduc-
ible among the different facilities, as demonstrated by
the non-significant variation (ps0.911 by Kruskal-
Wallis test) and the excellent correlation shown by
Passing and Bablok regression analysis and the Pear-
son correlation coefficient (Table 5). The triplicate
measurements using instruments providing semi-
quantitative HI results were always identical for all the
samples tested. For those instruments providing
quantitative HI results, the mean intra-assay coeffi-
cient of variation (CVs) calculated for the triplicate
determinations were 1.2% for the Modular System P,
2.7% for the Integra 400 Plus, 0.1% for the ADVIA 2400
and 1.0% for the ADVIA 1800, respectively.
Discussion
The receipt of hemolyzed samples in clinical labora-
tories is common and their identification is often dif-
ficult, especially when using arbitrary procedures
such as the visual inspection. Detection of unsuitable
specimens is even more challenging, if not impossi-
ble, when using whole blood specimens on point of
care (POC) devices. Discrepant potassium results
between POC devices and conventional laboratory
instrumentation, rarely recorded, might be due to
unrecognized in vitro hemolysis (11). Although quan-
titation of free hemoglobin in serum or plasma is the-
oretically possible by immunonephelometry (12), the
use of this approach on all samples referred for test-
ing is unpractical due to resultant increases in turna-
round time, unavailability of the assay on instruments
and uneconomical. Therefore, to simplify and stan-
dardize the process of identification of hemolyzed
samples, and to evaluate their suitability for testing,
automated detection of spectrophotometric interfe-
rents in patient serum and plasma caused by hemo-
lysis, as well as by icterus and lipemia, have been
developed. These systems consist of rapid, simple
and inexpensive spectrophotometric blanked bichro-
matic measurements, most frequently between
405 nm and 700 nm (13). These flexible features are
designed to provide users with an optional, automat-
ed and unbiased means of identification, so that
unsuitable specimens can be dealt with according to
the best laboratory practice. There is little doubt that
the widespread implementation of the HI, as well as
other serum indexes, would be advantageous and
profitable for a variety of reasons. These include the
rapid detection of in vivo or in vitro hemolysis and
the assessment of potential interference from hemo-
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Table 5 Passing and Bablok regression analysis and Pearson correlation coefficient for the HI assayed on the four Roche
Modular System P platforms.
Padova Leuven Hradec Kralove
Verona ys0.994x ys1.104xq0.01 ys1.021x
rs1.00; p-0.001 rs1.00; p-0.001 rs1.00; p-0.001
Padova – ys1.111x ys1.029x–0.01
rs1.00; p-0.001 rs1.00; p-0.001
Leuven – – ys0.923x
rs1.00; p-0.001
globin-based oxygen carriers (14), which would ulti-
mately help diminish uncertainty in the preanalytical
phase, enhance the quality in laboratory diagnostics,
and reduce the chance of errors that can jeopardize
the patient safety (7). Although the approach has been
previously questioned (7), it is necessary to mention
that the availability of quantitative results of hemo-
globin in the samples might allow the use of formulas
for correcting biases due to interference from hemo-
lysis (15).
Although most preanalytical workstations and
clinical chemistry platforms are now equipped with
automatic systems for detecting, and some for quan-
titating interferents, no studies have previously
assessed imprecision and reproducibility of these
measures among facilities and, especially, among dif-
ferent instruments and manufacturers. The results of
this multicenter evaluation demonstrate that overall
imprecision of the instruments tested is satisfactory,
as shown by inter-assay CVs between 0.1% and 2.7%.
We have also shown that the reproducibility among
different facilities using the same instrument (Modu-
lar System P) is excellent. The overall instrument-
specific efficiency for identifying unsuitable samples
was highly comparable, and no false negative results
occurred when analyzing samples with free hemoglo-
bin concentrations )0.6 g/L. Likewise, all instruments
except for the RxL Dimension correctly classified sam-
ple B, with a hemoglobin concentration of 0.048 g/L
as measured by the cyanmethemoglobin method,
suitable for testing. These results are of particular sig-
nificance in situations such as total laboratory auto-
mation or in laboratories where the preanalytical
workstations are connected directly to the analytical
platform and workflow makes visual inspection vir-
tually impossible. However, we have also demon-
strated that more efforts should be placed on
standardization of reporting of HI. In addition to pre-
vious concerns that have been raised regarding the
sometimes arbitrary and lack of evidence-based cut-
offs to define the limits at which clinically significant
interference starts (16), all the instruments that we
tested provide either quantitative or qualitative results
that are roughly comparable, but which should
always be linked to the instrument-specific alert value
for each test in order to harmonize and streamline
their effectiveness (Tables 3 and 4). It is also impor-
tant to highlight that it is necessary to evaluate the
influence of hemolysis for each test and to state the
limits of acceptability for each, as proposed in some
validation protocols (17, 18). Unfortunately, we could
not evaluate the HI on other instruments than those
available to the participants of the study group. Thus,
these results might not be universally applicable to
other testing systems.
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